KIMBERLY VELIE: Open Payments
NPI 1275109605 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$653 in 32 payments from 10 companies in 2025. Trend: 2023 $211 · 2024 $99 · 2025 $653
Food & beverage: $653
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $243 |
| Vanda Pharmaceuticals Inc. | 7 | $151 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $76 |
| ABBVIE INC. | 3 | $53 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Biogen, Inc. | 1 | $26 |
| JAZZ PHARMACEUTICALS INC. | 1 | $17 |
| Janssen Pharmaceuticals, Inc | 1 | $16 |
| Neurocrine BioSciences, Inc. | 1 | $14 |
Products named: REXULTI, FANAPT, CAPLYTA, VRAYLAR, ABILIFY MAINTENA, REJOYN, Auvelity, LEQEMBI.
Industry payments across AL — which companies pay providers there.
